We are analyzing https://link.springer.com/article/10.1007/s00262-008-0555-9.

Title:
Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth | Cancer Immunology, Immunotherapy
Description:
Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Education
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 8,170,236 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, pubmed, cas, typhimurium, cancer, salmonella, attenuated, chemokine, cells, ccl, tumor, immunol, loeffler, reed, tumors, antitumor, access, growth, bacteria, privacy, cookies, content, administration, cell, vivo, clin, med, information, publish, research, search, engineered, produce, july, lenegrate, krajewska, john, murine, chemokines, cxcl, open, res, sci, dendritic, lymphoid, strieter, analysis, data,

Topics {✒️}

multi-drug-resistant murine carcinomas tumor-targeting salmonella typhimurium month download article/chapter cell-dependent antitumor responses lymphocyte-specific cc chemokine ckbeta-11/mip-3beta/elc endothelial-target rickettsial infections increase anti-tumor activity article cancer immunology slc/6ckine/exodus2/tca4 vivo-derived dendritic cells vivo immuno-depletion experiments attenuated salmonella typhimurium genetically modified strain related subjects cxcl9/10-cxcr3 chemokine system attenuated salmonella engineered full article pdf salmonella typhimurium engineered anti-tumor activity privacy choices/manage cookies human il-1 beta interferon-inducible protein 10 superficial bladder cancer confers tumor immunity macrophage tumoricidal activities targeting tumor live animals antitumor agent vnp20009 preclinical models tumour progression recombinant therapeutic proteins article loeffler tumor growth attenuated strain attenuated bacteria salmonella typhimurium european economic area check access bacillus prodigosus t1g3 bladder tumours immunological urinary measurements highly efficient chemoattractant considered senior authors instant access chemokine ccl21 conditions privacy policy significant adverse effects dendritic cells author information authors

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth
         description:Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins.
         datePublished:2008-07-17T00:00:00Z
         dateModified:2008-07-17T00:00:00Z
         pageStart:769
         pageEnd:775
         sameAs:https://doi.org/10.1007/s00262-008-0555-9
         keywords:
             Salmonella
            CCL21
            Cancer therapy
            Bacterial therapy
            Tumor targeting
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig3_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Markus Loeffler
               affiliation:
                     name:Burnham Institute for Medical Research
                     address:
                        name:Burnham Institute for Medical Research, La Jolla, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gaelle Le’Negrate
               affiliation:
                     name:Burnham Institute for Medical Research
                     address:
                        name:Burnham Institute for Medical Research, La Jolla, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maryla Krajewska
               affiliation:
                     name:Burnham Institute for Medical Research
                     address:
                        name:Burnham Institute for Medical Research, La Jolla, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John C. Reed
               affiliation:
                     name:Burnham Institute for Medical Research
                     address:
                        name:Burnham Institute for Medical Research, La Jolla, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth
      description:Intravenously-applied bacteria tend to accumulate in tumors and can sporadically lead to tumor regression. Systemic administration of attenuated Salmonella typhimurium is safe and has shown no significant adverse effects in humans. The purpose of this study was to test the hypothesis that engineering S. typhimurium to express a chemokine, CCL21, would increase anti-tumor activity. We engineered an attenuated strain of S. typhimurium to produce the chemokine CCL21. Attenuated S. typhimurium expressing CCL21 significantly inhibited the growth of primary tumors and pulmonary metastases in preclinical models of multi-drug-resistant murine carcinomas, while control bacteria did not. Histological analysis of tumors showed marked inflammatory cell infiltrates in mice treated with CCL21-expressing but not control bacteria. Levels of cytokines and chemokines known to be induced by CCL21 [e.g., interferon-γ (INFγ), CXCL9, and CXCL10] were significantly elevated in tumors of mice treated with CCL21-expressing but not control S. typhimurium. The anti-tumor activity was found to be dependent on CD4- and CD8-expressing cells, based on antibody-mediated in vivo immuno-depletion experiments. Anti-tumor activity was achieved without evidence of toxicity. In summary, chemokine-expressing, attenuated bacteria may provide a novel approach to cancer immunotherapy for effective and well-tolerated in vivo delivery of immunomodulatory proteins.
      datePublished:2008-07-17T00:00:00Z
      dateModified:2008-07-17T00:00:00Z
      pageStart:769
      pageEnd:775
      sameAs:https://doi.org/10.1007/s00262-008-0555-9
      keywords:
          Salmonella
         CCL21
         Cancer therapy
         Bacterial therapy
         Tumor targeting
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0555-9/MediaObjects/262_2008_555_Fig3_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Markus Loeffler
            affiliation:
                  name:Burnham Institute for Medical Research
                  address:
                     name:Burnham Institute for Medical Research, La Jolla, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gaelle Le’Negrate
            affiliation:
                  name:Burnham Institute for Medical Research
                  address:
                     name:Burnham Institute for Medical Research, La Jolla, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maryla Krajewska
            affiliation:
                  name:Burnham Institute for Medical Research
                  address:
                     name:Burnham Institute for Medical Research, La Jolla, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John C. Reed
            affiliation:
                  name:Burnham Institute for Medical Research
                  address:
                     name:Burnham Institute for Medical Research, La Jolla, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Burnham Institute for Medical Research
      address:
         name:Burnham Institute for Medical Research, La Jolla, USA
         type:PostalAddress
      name:Burnham Institute for Medical Research
      address:
         name:Burnham Institute for Medical Research, La Jolla, USA
         type:PostalAddress
      name:Burnham Institute for Medical Research
      address:
         name:Burnham Institute for Medical Research, La Jolla, USA
         type:PostalAddress
      name:Burnham Institute for Medical Research
      address:
         name:Burnham Institute for Medical Research, La Jolla, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Markus Loeffler
      affiliation:
            name:Burnham Institute for Medical Research
            address:
               name:Burnham Institute for Medical Research, La Jolla, USA
               type:PostalAddress
            type:Organization
      name:Gaelle Le’Negrate
      affiliation:
            name:Burnham Institute for Medical Research
            address:
               name:Burnham Institute for Medical Research, La Jolla, USA
               type:PostalAddress
            type:Organization
      name:Maryla Krajewska
      affiliation:
            name:Burnham Institute for Medical Research
            address:
               name:Burnham Institute for Medical Research, La Jolla, USA
               type:PostalAddress
            type:Organization
      name:John C. Reed
      affiliation:
            name:Burnham Institute for Medical Research
            address:
               name:Burnham Institute for Medical Research, La Jolla, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Burnham Institute for Medical Research, La Jolla, USA
      name:Burnham Institute for Medical Research, La Jolla, USA
      name:Burnham Institute for Medical Research, La Jolla, USA
      name:Burnham Institute for Medical Research, La Jolla, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(109)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.23s.

LINK . SPRINGER . COM {}